Abstract
The serum levels of soluble tumor necrosis factor receptor I (sTNF-RI) were measured in 74 noncachectic patients including 42 with gastric cancer and 32 with colorectal cancer, as well as in 39 patients with severe cachexia and 15 healthy volunteers. The sTNF-RI levels increased with the advance of disease, being highest in the cachectic patients. The levels were inversely correlated with the serum concentrations of nutritional parameters such as prealbumin, transferrin, retinol binding protein, and the percentages of CD3(+) cells in the peripheral blood lymphocytes, and positively correlated with the serum concentration of immunosuppressive acidic protein (IAP) and soluble interleukin-2 receptors. These findings suggest that sTNF-RI could be an important prognostic factor to predict the advance of gastric and colorectal cancers and deterioration of the patient’s nutritional and immune activity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lawson DH, Richmond A, Nixon DW, Rudman D (1982) Metabolic approaches to cancer cachexia. Annu Rev Nutr 2:277–301
Van Eys J (1985) Nutrition and cancer: physiological interrelationships. Annu Rev Nutr 5:435–461
Wesdorp RIC, Krause R, Von Meyenfeldt M (1983) Cancer cachexia and its nutritional implications. Br J Surg 70:352–355
Kern AK, Norton JA (1988) Cancer cachexia. J Parent Enteral Nutr 12:286–298
Moldawer LL, Georgieff M, Lundholm K (1987) Interleukin 1, tumour necrosis factor-α (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol 7:263–274
Oliff A (1988) The role of tumor necrosis factor (cachectin) in cachexia. Cell 54:141–142
Beutler B, Greenwalt D, Humes JD, Chang M, Pan Y-CE, Mathison J, Ulevitch R, Cerami A (1985) Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552–554
Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B (1985) Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 11:173–177
Tartaglia LA, Goeddel DV (1992) Two TNF receptors. Immunol Today 13:151–153
Engelmann H-P, Novick D, Wallach D (1990) Tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531–1536
Engelmann H, Holtmann H, Brakebusch C, Avni YS, Sarov I, Naphar Y, Hadas E, Leitner O, Wallach D (1990) Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 265:14497–14504
Nophar Y, Kemper O, Brakebusch C, Engelmann H, Zwang R, Aderka D, Holtmann H, Wallach D (1990) Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned suing amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 9:3269–3278
Porteu F, Nathan C (1990) Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med 172:599–607
Lantz M, Gullberg U, Nilsson E, Olsson I (1990) Characterization in vitro of a human tumor necrosis factor binding protein: a soluble form of a tumor necrosis factor receptor. J Clin Invest 86:1396–1402
Van Ostade X, Vandenabeele P, Everaerdt B, Loetscher H, Gentz R, Brockhaus M, Lesslauer W, Tavernier J, Brockaert P, Fiers W (1993) Human TNF mutants with selective activity on the p55 receptor. Nature 361:266–269
Hahn T, Toker L, Budilovsky S, Aderka D, Eshhar Z, Wallach D (1985) Use of a monoclonal antibody of a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proc Natl Acad Sci USA 82:3814–3818
Nophar Y, Holtmann H, Ber R, Wallach D (1988) Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. J Immunol 140:3456–3460
Wallach D, Holtmann H, Engelmann H, Nophar Y (1988) Sensitization and desensitization to lethal effects of tumor necrosis factor and of interleukin-1. J Immunol 140:2994–2999
Japanese Research Society for Cancer of the Stomach (1993) General rules for clinical and pathological studies on cancer of the stomach (12th edn.) Kanehara, Tokyo
Japanese Research Society for Cancer of the Colon and Rectum (1994) General rules for clinical and pathological studies on cancer of the colon, rectum and anus (5th edn.) Kanehara, Tokyo
Langkopf F, Atzpodien J (1994) Soluble tumour necrosis factor receptors as prognostic factors in cancer patients. Lancet 344:57–58
Aderka D, Engelmann H, Hornik V, Skornik Y, Levo Y, Wallach D, Kushtai G (1991) Increased serum levels of soluble forms for tumor necrosis factor in cancer patients. Cancer Res 51:5602–5607
Brivio F, Lissoni P, Mancini D (1991) Effect of antitumor surgery on soluble interleukin-2 receptor serum levels. Am J Surg 161:466–469
Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL (1985) Soluble interleukin 2 receptors are released by activated human lymphoid cells in vitro. J Immunol 135:3172–3176
Rovelli F, Lissoni P, Crispino S (1988) Increased level of soluble interleukin-2 receptor in advanced solid tumors: a preliminary study. Tumori 74:633–637
Denz, H, Orth B, Weiss G, Herrmann R, Huber P, Wachter H Fuchs D (1993) Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clin Invest 71:37–41
Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A, Adolf G (1989) Isolation and characterization of a tumor necrosis binding protein from urine. Eur J Haematol 42:270–275
Rogy MA, Coyle SM, Oldenburg HSA, Rock CS, Barie PS, Van Zee KJ, Smith CG, Moldawer LL, Lowry SF (1994) Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 178:132–138
Engelmann E, Aderka D, Rubinstein M, Rotmann D, Wallach D (1989) A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 264:11974–11980
Seckinger P, Isaaz S, and Daye, J-M (1989) Purification and biologic characterization of a specific tumor necrosis factor inhibitor. J Biol Chem 264:11966–11973
Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF (1992) Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor á in vitro and in vivo. Proc Natl Acad Sci USA 89:4845–4849
Billiau A (1988) γ-interferon: the match that lights the fire? Immunol Today 9:37–40
Patton JS, Shepard HM, Wilking H, Lewis G, Aggarwal BB, Eessalu TE, Gavin LA, Grunfeld C (1986) Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proc Natl Acad Sci USA 83:8313–8317
Langstein HN, Doherty GM, Fraker DL, Buresh GM, Norton JA (1991) The roles of ç-interferon and tumor necrosis factor á in an experimental rat model of cancer cachexia. Cancer Res 51: 2302–2306
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shibata, M., Takekawa, M. & Amano, S. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer. Surg Today 28, 884–888 (1998). https://doi.org/10.1007/s005950050247
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s005950050247